Equivalent trends were observed for the instances of combined P53-MYC alterations detected in relapsed MBWNT and MBGroup3 tumors (one of two tumors in both groups); these defects were not observed in any tumor sampled at diagnosis (0/48 [p = 0.0400] and 0/124 [p = 0.0159], respectively, Figure 2B). This evidence concerns the gene MYC and neoplasm.